Renovacor, Inc.

Chardan NexTech Acquisition 2 Corp, trading under the ticker CHAQ and sponsored by Chardan NexTech, filed an 8-K with the SEC on September 2, 2021, in connection with its proposed business combination with Renovacor, Inc., a clinical-stage genetic medicine company focused on cardiovascular disease and heart failure gene therapy. The blank-check company, which completed its IPO in 2020, targeted the healthcare and life sciences sector. The filing, carrying accession number 0001193125-21-264487, reflects a key milestone in CHAQ's de-SPAC process as it moved toward a definitive transaction. Sign up at SpacDesk for complete filing history, deal timelines, and sponsor analytics on CHAQ and hundreds of other SPACs.